Effects of Ischemic Preconditioning on Muscle Damage Induced by Excentric Exercise

April 19, 2022 updated by: Franciele Marques Vanderle, Paulista University

Effects of Ischemic Preconditioning on Muscle Damage Induced by Excentric Exercise: Randomized Clinical Trial Placebo Controlled

Introduction: eccentric exercise (EE) has been widely used in rehabilitation and in improving physical fitness due to its mechanical advantage and less metabolic demand, however, EE can induce muscle damage providing structural changes and reduced muscle function, therefore, it is necessary to look for alternatives to reduce this damage caused by stress. Thus, ischemic preconditioning (PCI) can be seen as an aid in reducing the damage caused by EE, as it can attenuate the ischemia-reperfusion injury, and can be used to accelerate the post-exercise recovery process. Objectives: to compare the effects of PCI, using different occlusion pressures, on acute and late responses to perceptual outcomes and muscle injury markers, in addition to checking whether the technique causes deleterious effects on performance in post-exercise recovery. Methods: a randomized placebo controlled clinical trial will be conducted with 80 healthy men aged 18 to 35 years who will be randomly divided into four groups: PCI using total occlusion pressure (POT), PCI with 40% more than POT, placebo (10 mmHg) and control. The PCI protocol will consist of four cycles of ischemia and reperfusion of five minutes each. All groups will perform an EE protocol, initial assessments, immediately after the end of the EE, 24, 48, 72 and 96 hours after exercise, with the maximum isometric voluntary contraction (CVIM) assessed by the isokinetic dynamometer, vectors of cell integrity by by means of electrical bioimpedance (BIA), creatine kinase (CK), blood lactate, pain on the visual analog scale (VAS), pain threshold by the pressure algometer, and tone, muscle rigidity and elasticity by myotonometry. The descriptive statistical method and analysis of variance will be used for the repeated measures model. The level of significance will be p <0.05.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • SP
      • Presidente Prudente, SP, Brazil, 55
        • Franciele Marques Vanderlei

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • not having any health condition that contraindicates or prevents EE;
  • not having diagnosed diabetes and high blood pressure;
  • not having inflammatory, psychiatric, cardiovascular and / or respiratory rheumatic disease;
  • not being an alcoholic, using drugs and / or a smoker;
  • without a history of knee surgery (for example, meniscal repair and ligament reconstruction) or recent musculoskeletal injury to the lower limbs that may impair performance during tests or interventions (for example, muscle injury, tendinopathy, patellofemoral pain in the lower limbs and / or back pain in the last six months);
  • without involvement in any type of training program during the study period;
  • not being engaged in the lower limb strength training program during the three months prior to participating in the study;
  • not using ergogenic supplements to improve physical performance and / or muscle mass and / or vasoactive drugs;
  • not having one or more risk factors predisposing to thromboembolism.

Exclusion Criteria:

  • present a health problem that does not allow continuity,
  • use medication, electrotherapy or other therapeutic means that may interfere with any result;
  • perform unusual or strenuous physical activities during the evaluation period;
  • want to leave the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: IPC-LOP
this group will carry out the baseline assessments, perform the ischemic preconditioning using exactly the limb occlusion pressure , then perform post-IPC assessments and start the excentric exercise, and the post-exercise assessments will take place immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff
EXPERIMENTAL: IPC-40%
this group will carry out baseline assessments, perform IPC using 40% more occlusion than LOP, then perform assessments after IPC protocol and start EE, and post exercise assessments will take place immediately after the end of EE and will be repeated in 24h, 48h, 72h and 96h.
The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff
PLACEBO_COMPARATOR: IPC-10mmHg:
this group will perform baseline assessments, perform occlusion-perfusion intervention with 10 mmHg restriction characterizing the placebo, then perform post-IPC assessments and initiate EE, and post-exercise assessments will take place immediately after completion of EE and if will repeat in 24h, 48h, 72h and 96h.
The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff
NO_INTERVENTION: CONTR
this group will carry out the baseline assessments, immediately after starting the EE, and the post-exercise assessments will happen immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle damage
Time Frame: Change from baseline at 96 hours after exercise
Plasma CK concentration will be obtained by means of 32 μL of capillary blood collected from the digital pulp.
Change from baseline at 96 hours after exercise
Blood lactate concentration
Time Frame: Change from baseline at 96 hours after exercise
Blood lactate concentration of the participant will be collected 25 ml of blood with an ear lobe capillary
Change from baseline at 96 hours after exercise
Muscle strength in isokinetic
Time Frame: Change from baseline at 96 hours after exercise
Maximal voluntary isometric contraction (MVIC)
Change from baseline at 96 hours after exercise

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle pain
Time Frame: Change from baseline at 96 hours after exercise
Assessed using a visual analog scale that ranges from 0 to 10 points, the higher the score, the worse the result.
Change from baseline at 96 hours after exercise
Pain threshold
Time Frame: Change from baseline at 96 hours after exercise
Assessed using pressure algometer equipment, and the pain threshold will be classified according to the cut-off point of 2.55kgf. Participants will be classified as "sensitive to pain" if they have values below 2.55kgf.
Change from baseline at 96 hours after exercise
Resistance through Bioimpedance analysis (BIA)
Time Frame: Change from baseline at 96 hours after exercise
Evaluation of tissue resistance, the higher the value, the worse the result
Change from baseline at 96 hours after exercise
Reactance through Bioimpedance analysis (BIA)
Time Frame: Change from baseline at 96 hours after exercise
Evaluation of tissue reactance, the higher the value, the better the cell integrity
Change from baseline at 96 hours after exercise
Phase angle through Bioimpedance analysis (BIA)
Time Frame: Change from baseline at 96 hours after exercise
Assessment of the phase angle, the higher the value, the better the condition of the participant
Change from baseline at 96 hours after exercise
Tone muscular through Myotonometry used the MyotonPRO equipment
Time Frame: Change from baseline at 96 hours after exercise
Natural Oscillation Frequency [Hz], characterizing Tone of the quadriceps femoris muscle
Change from baseline at 96 hours after exercise
Stiffness through Myotonometry used the MyotonPRO equipment
Time Frame: Change from baseline at 96 hours after exercise
Dynamic Stiffness [N/m] of the quadriceps femoris muscle
Change from baseline at 96 hours after exercise
Elasticity through Myotonometry used the MyotonPRO equipment
Time Frame: Change from baseline at 96 hours after exercise
Mechanical Stress Relaxation Time [ms] featuring muscle elasticity of the quadriceps femoris muscle
Change from baseline at 96 hours after exercise
Perception of recovery
Time Frame: Change from baseline at 96 hours after exercise
Perception of recovery was obtained using a 10-point Likert Scale, with a rating of 1 indicating the feeling "not recovered" and a rating of 10 the feeling "fully recovered"
Change from baseline at 96 hours after exercise

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 1, 2021

Primary Completion (ACTUAL)

December 1, 2021

Study Completion (ACTUAL)

April 1, 2022

Study Registration Dates

First Submitted

May 29, 2020

First Submitted That Met QC Criteria

June 3, 2020

First Posted (ACTUAL)

June 9, 2020

Study Record Updates

Last Update Posted (ACTUAL)

April 26, 2022

Last Update Submitted That Met QC Criteria

April 19, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Ischemic Preconditioning

3
Subscribe